Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q1 FY2026 Earnings Presentation
29 slides from Metropolis Healthcare's earnings presentation, Aug 7, 2025
Slide 1: Exchange filing cover letter
Ref: MHL/Sec&Legal/2025-26/47 August 07, 2025 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are
Slide 2: Metropolis Healthcare Limited Q1FY26 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q1FY26 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand 43+ years of trusted by clinicians, patients and 11% CAGR stakeholders. credible revenue experience Positively impact the lives of patients in growth in last their most anxious times a
Slide 5: Performance & Company Updates – Q1FY26
Performance & Company Updates – Q1FY26 Important Updates & Definitions: 1. MHL Group – Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra MHL Group MHL Organic 2. MHL Organic – Excludes recent 01 Key Financials (Page 4) 07 Speciality Business (Page 12)
Slide 6: Q1FY26 Key Financials – MHL Group
Q1FY26 Key Financials – MHL Group • Revenue growth fueled by organic & recent acquisitions • Q1FY26, EBITDA margin at group level stood at 23.1% Revenue EBITDA PAT • Core Diagnostics EBITDA Margins turned positive and is on a growth INR 386 Cr INR 89 Cr INR 45 Cr trajectory +23% YoY +14% YoY +19% Yo
Slide 7: Q1FY26 Key Financials – MHL Organic
Q1FY26 Key Financials – MHL Organic • Organic revenue grew in double digits consistently, outpacing industry trends • Growth was driven by higher Revenue EBITDA PAT network productivity, scientific upselling, and micro-market- focused execution. INR 355 Cr INR 88 Cr INR 46 Cr +13% YoY • Q1FY26 EBITD
Slide 8: Q1FY26 Key Performance Indicators MHL Organic
Q1FY26 Key Performance Indicators MHL Organic Excludes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra 6
Slide 9: Q1FY26 Key Performance Indicators
Q1FY26 Key Performance Indicators Patient Volume B2C Revenue B2B Revenue • Patient and test volumes rebounded, with June recording 8% 3.2 Mn INR 209 Cr patient volume growth INR 146 Cr +7% YoY +16% YoY +10% YoY • Strong B2C revenue growth driven by intensified clinician and community engagement • B2
Slide 10: Consistently Delivering Patient & Test Volume Growth
Consistently Delivering Patient & Test Volume Growth Patient Volume (in Mn) Test Volume (in Mn) Q1FY26 Segment Contribution Q1FY26 Segment Revenue Growth 9.7% Routine 8% 7% 6% 8% Routine 18% 17% Semi-Special Semi-Special 8% 3.03 3.23 6.28 6.79 Specialty 27% Specialty 16% 38% TruHealth TruHealth 22%
Slide 11: Strong B2C revenue growth @ 16% YoY
Strong B2C revenue growth @ 16% YoY • B2C patient volume grew 9%, with a 6% increase in revenue per patient, driven by high- value scientific upselling 59% • B2C TruHealth and Specialty (+120bps) +19% segments led growth, powered by new test additions and our Next Best Action engine +16% +18% • App
Slide 12: B2B revenue growing by 10% YoY
B2B revenue growing by 10% YoY • B2B patient volumes grew 4%, with a 6% rise in RPP, supported by hospital-led high-value outsourcing 41% • Clinical trial business, +46% delivered strong contribution, aligning with our specialty +10% +15% focus • Corporate partnerships and outreach initiatives expan
Slide 13: TruHealth Revenue grew @ 22% YoY for Q1FY26
TruHealth Revenue grew @ 22% YoY for Q1FY26 o Strong Revenue and Volume Momentum with high-end integrated packages underscoring successful premium positioning Growth • ~1.5X revenue growth QoQ from premium TruHealth wellness packages integrated with home-based ECG, vital checks, and consultations •
Slide 14: Speciality Revenue grew @ 16% YoY for Q1FY26
Speciality Revenue grew @ 16% YoY for Q1FY26 o Innovation-Led Launches with Market Differentiation Specialty Growth • Launched Hereditary Cancer Panel and new bundled Onco-360 profiles as preventive screening. Expanded Neurological Portfolio with new tests for disease segments o AI-based and assiste
Slide 15: Q1FY26 Key Performance Indicators MHL Group
Q1FY26 Key Performance Indicators MHL Group Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra 13
Slide 16: Q1FY26 Key Performance Indicators
Q1FY26 Key Performance Indicators Q1FY26 Segment Contribution Patient Volume B2C Revenue B2B Revenue 17% 17% Routine Semi-Special 3.4 Mn INR 214 Cr INR 172 Cr Specialty +11% YoY +19% YoY +29% YoY TruHealth 27% 39% Q1FY26 Segment Revenue Growth Test Volume RPT RPP Routine 20% 7.1 Mn INR 546 INR 1,151
Slide 17: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Contribution from North India has increased to 17% Revenue Contribution Revenue Contribution (MHL Categorisation) By Region South 30% 27% East Q1FY25 52% Q1FY26 56% 5% North 5% West 9% 17% Revenue Contribution Revenue Contribution (MHL Categorisati
Slide 18: Network Expansion – Robust expansion with consolidation laying strong base
Network Expansion – Robust expansion with consolidation laying strong base Laboratory Network Service Network 210 222 199 4,150 4,536 4,616 175 3,675 161 870 890 +2,061 +97 805 3,134 754 119 124 125 2,731 2,555 2,336 704 Centres Labs 575 598 498 3,135 3,161 2,914 2,594 2,105 Rural 1,873 1,806 1,506
Slide 19: Q1 FY26 Profit & Loss Statement
Q1 FY26 Profit & Loss Statement Q1FY26 Q1FY26 Profit & Loss Statement (Rs. Crs.) Q1FY25 Y-o-Y Y-o-Y (MHL Organic) (MHL Group) Revenue from Operations 313.4 354.8 13.2% 386.1 23.2% Total Cost 235.2 267.2 296.9 Reported EBITDA 78.2 87.5 11.9% 89.1 14.0% Reported EBITDA (%) 25.0% 24.7% 23.1% Depreciati
Slide 20: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 21: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 2 Strengthening the Core Expand to Adjacencies Expand market share in core and while Forging New Alliances new geographies with focus on Expand into adjacencies such as specialized and wellness testing, complementary radiology and pri
Slide 22: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient 360- Opportunity Case Relationship Reporting & Cross Enhanced Efficient Billing & Patient Personalizatio
Slide 23: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology 48+ New Tests added in Q1FY26 and Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven (
Slide 24: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener • 45% reduction in emissions intensity Well identified ESG Focus Areas and Tomorrow by 2030 e assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. • Zero waste in offices by 2030 Ac
Slide 25: Key ESG Plans
Key ESG Plans Emissions & Water & Waste Employee Risk Patient Privacy Energy Management Recruitment, Management and Electronic Development and Health Records • Achieve 10% reduction Retention in energy consumption • Achieve 5% reduction • Career 2.0 Campaign to • Annual assessments of • 100% trainin
Slide 26: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive MedEngage Too Shy to Ask(TSTA) healthcare Project • 365 Scholarships supported the with • TSTA Rural focusing on adolescent MedEngage scholarship support. including reproductive and sexual health, and life • 1000 TB patients to receive nutrit
Slide 27: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Sameer Patel Diya Suri Dr. K
Slide 28: Recent Awards and Accolades
Recent Awards and Accolades Metropolis Healthcare – Most Innovative Organizations Award by ET Now for Jun’25 the year 2025 Metropolis Healthcare – Best Healthcare Brands Award by ET Edge for the year Jun’25 2025 Metropolis Healthcare - Gold Award for Best Diagnostic Chain of the Year Jun’25 2025 at
Slide 29: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q1 FY2026 Earnings Presentation on 6ix